Search results for " Ki-67"

showing 9 items of 9 documents

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

2021

The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Mei…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMultivariate analysisNeutrophilsQH301-705.5medicine.medical_treatmentBreast NeoplasmsArticleDisease-Free Survivalpredictive/prognostic biomarkers03 medical and health sciences0302 clinical medicineText miningBreast cancerluminal breast cancerInternal medicineMedicineHumansLymphocytesNeutrophil to lymphocyte ratioBiology (General)Neoadjuvant therapyAgedRetrospective StudiesChemotherapybusiness.industryProportional hazards modelallergologyfungiLuminal breast cancer; Neoadjuvant chemotherapy; Neutrophil to lymphocyte ratio (NLR); Predictive/prognostic biomarkers; Adult; Aged; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Lymphocytes; Middle Aged; Multivariate Analysis; Neutrophils; Prognosis; Retrospective Studies; Treatment Outcome; Neoadjuvant TherapyHistologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisneutrophil to lymphocyte ratio (NLR)Neoadjuvant Therapy030104 developmental biologyKi-67 AntigenTreatment Outcome030220 oncology & carcinogenesisMultivariate AnalysisPopulation studyFemalebusinessneoadjuvant chemotherapy
researchProduct

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

p53 and Ki-67 expression in renal cell carcinomas of pregnant women and their correlation with prognosis: a pilot study.

2007

In the present study, we reported two cases of renal cell carcinoma (RCC) diagnosed in pregnant women (Pt) that were submitted to radical nephrectomy, in both cases within the fourth month. The patients, after 13 and 3 years, respectively, did not show evidence of recurrent disease. We performed an immunohistochemical study on RCC specimens in comparison to seven age-matched controls (Cl). The panel of antibodies included Ki-67, p53, bcl-2, ER, PgR, PCNA, and IGF-1. We describe a difference in the expression of p53 and Ki-67. Specifically, p53 was highly expressed in RCC of both Pt but scarcely present or absent in Cl; by contrast, Ki-67 was hardly expressed or negative in RCC of both Pt, b…

Adultmedicine.medical_specialtyPathologymedicine.medical_treatmentPilot ProjectsDiseaseGastroenterologyNephrectomyImmunoenzyme Techniquescarcinomas prognosisRenal cell carcinomaPregnancyInternal medicinemedicineBiomarkers TumorHumansCarcinoma Renal CellKEYWORDS: IGF-1 Ki-67 pregnancy p53 protein renal cell carcinoma.Pregnancybiologybusiness.industryObstetrics and Gynecologymedicine.diseasePrognosisNephrectomyKidney NeoplasmsProliferating cell nuclear antigenKi-67 AntigenOncologyKi-67biology.proteinImmunohistochemistryFemalePregnant WomenAntibodyTumor Suppressor Protein p53businessPregnancy Complications Neoplastic
researchProduct

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme

2008

Abstract Purpose: Cancer stem cells (CSC) are thought to represent the population of tumorigenic cells responsible for tumor development. The stem cell antigen CD133 identifies such a tumorigenic population in a subset of glioblastoma patients. We conducted a prospective study to explore the prognostic potential of CSC analysis in glioblastoma patients. Experimental Design: We investigated the relationship between the in vitro growth potential of glioblastoma CSCs and patient death or disease progression in tumors of 44 consecutive glioblastoma patients treated with complete or partial tumorectomy followed by radiotherapy combined with temozolomide treatment. Moreover, we evaluated by immun…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPathologyAC133 Antigen; Adult; Aged; Antigens CD; Brain Neoplasms; Female; Glioblastoma; Glycoproteins; Humans; Ki-67 Antigen; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; Peptides; Prospective Studiesmedicine.medical_treatmentPopulationAntigens CDCancer stem cellInternal medicinemedicineHumansAC133 AntigenProspective StudiesAntigensProspective cohort studyeducationAgedGlycoproteinseducation.field_of_studyTemozolomideSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryBrain NeoplasmsHazard ratioMiddle AgedGliobastoma MultiformeCDRadiation therapyKi-67 AntigenOncologyMultivariate AnalysisNeoplastic Stem CellsImmunohistochemistryFemaleStem cellbusinessGlioblastomaPeptidesmedicine.drug
researchProduct

Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors

2012

Objectives: The aim of this study was to compare among PCNAand Ki-67 as the most reliable immunohisto chemical marker for evaluating cell proliferation in ameloblastic tumors. Study Design: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com- D esign: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com- esign: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com posed of 161 ameloblastomas and four ameloblastic carcinomas, to determine and compare PCNA and Ki-67 expression using immunohistochemistry techniques. Results: When analyzing Ki-67 positivity, the…

Pathologymedicine.medical_specialtyCARCINOMADesmoplastic ameloblastomagovernment.form_of_governmentOdontologíaAmeloblastomaANTIGENO NUCLEAR DE CELULA EN PROLIFERACIONChemical markerCell proliferation markersstomatognathic systemProliferating Cell Nuclear AntigenProliferation ratemedicinePCNAHumansGeneral DentistryCell ProliferationRetrospective StudiesAmeloblastomasOral Medicine and PathologybiologyCell growthbusiness.industry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludANTIGENO Ki-67Proliferating cell nuclear antigenAmeloblastic carcinomaKi-67 AntigenAMELOBLASTOMAOtorhinolaryngologyKi-67UNESCO::CIENCIAS MÉDICASbiology.proteingovernmentKi-67ImmunohistochemistryResearch-ArticleMouth NeoplasmsSurgerybusinessBiomarkersAmeloblastic carcinoma
researchProduct

Prognostic significance of standardized AgNOR analysis and Ki-67 immunostaining in gastrointestinal stromal tumors

2003

Abstract OBJECTIVE: To evaluate the prognostic utility of argyrophilic nucleolar organizer region (AgNOR) protein parameters and Ki-67-immunostained growth fraction (Ki-67 labelling index) and to correlate AgNORs with Ki-67 LI and the main clinicopathologic parameters in gastrointestinal stromal tumors (GISTs). STUDY DESIGN: On 55 patients with surgically excised GISTs, visualization and quantification of AgNORs were performed as specified in the guidelines of the Committee on AgNOR Quantification. RESULTS: AgNOR protein area (NORA) ≥5.28 μm2 was statistically associated with mitotic rate ≥5x10 high-power fields (hpfs) (P <.001) and presence of necrosis (P <.001); Ki-67 LI ≥9.69% was signif…

Prognostic significance of standardized AgNOR analysis and Ki-67 immunostaining in gastrointestinal stromal tumors
researchProduct

Expression of hMLH1 and hMSH2 proteins in ameloblastomas and tooth germs

2017

Background Mismatch repair proteins (MMRPs) are a group of nuclear enzymes that participate in the repair of base mismatches that occur during DNA replication in all proliferating cells. The most studied MMRPs are hMSH2 and hMLH1, which are known to be highly expressed in normal tissues. A loss of MMRPs leads to the accumulation of DNA replication errors in proliferating cells. Ki-67 is a biomarker regarded to be the gold-standard tool for determining cell proliferation by immunohistochemical methods. The aim of this study was to investigate the immunohistochemical expression of hMLH1, hMSH2 and Ki-67 proteins in ameloblastomas and tooth germs, to contribute to the understanding of the deve…

congenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyhMSH2hMLH1Ameloblastoma03 medical and health sciencesTooth germsGERMEN DENTARIO0302 clinical medicinemedicineHumansHOMOLOGO 1 DE LA PROTEINA MutL (1)AmeloblastomaGeneral DentistryTooth GermsOral Medicine and PathologyAmeloblastomasbiologyCell growthResearchDNA replicationTooth Germnutritional and metabolic diseases030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistryJaw NeoplasmsANTIGENO Ki-67PROTEINA 2 HOMOLOGA a MutS (1)digestive system diseasesKi-67 AntigenMutS Homolog 2 ProteinAMELOBLASTOMAOtorhinolaryngology030220 oncology & carcinogenesisKi-67UNESCO::CIENCIAS MÉDICASbiology.proteinKi-67Biomarker (medicine)ImmunohistochemistrySurgeryDNA mismatch repairMutL Protein Homolog 1Medicina Oral Patología Oral y Cirugia Bucal
researchProduct

Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma

2019

Background: CD8+ T cell responses are an essential component of the adaptive immune system. After resolution of infection a small population of memory cells is formed. In relation to circulatory patterns, different subsets of memory CD8+ T cells can be identified: the central memory (CM) and the effector memory T cells (EM) (Martin MD, et al., Front Immunol. 2018). In addition, it has been described a subset of resident memory T cells (TRM) permanently living in peripheral tissues, including the bone marrow (BM) (Di Rosa F., et al., Nat Rev Immunol. 2016). It is conceivable that these cells can contribute to the defence toward haematological tumours infiltrating the BM. Therefore, we perfor…

education.field_of_studymedicine.medical_treatmentT cellCD3ImmunologyPopulationCell BiologyHematologyBiologyBiochemistryMolecular biologySettore MED/15 - Malattie Del SangueCytokinemedicine.anatomical_structurebone marrow multiple myeloma t-lymphocytes memory cytokine interleukin-15 interleukin-7 cd45 antigens immunoglobulin a immunoglobulin g ki-67 antigenInterleukin 15medicinebiology.proteinCytotoxic T cellBone marroweducationCD8Blood
researchProduct

Malignancy course of pituitary adenoma in MEN1 syndrome: Clinical-Neuroradiological signs

2020

Pituitary carcinomas (PCa) are extremely rare, indistinguishable from pituitary adenomas on histopathological grounds and have a poor prognosis. Most PCa start as PRL or ACTH secreting tumors in males, with relapsing invasive behaviour, refractoriness to medical and radiotherapy and increasing hormonal levels. The presence of distant metastases is still required for the diagnosis of PCa. The association with genetic endocrine diseases must be taken into account, since it adds further risk of evolution towards malignancy. Intradural spinal metastases have also been reported, so a complete craniospinal MR evaluation is recommended, when clinically indicated. We report a case of PCa, associate…

lcsh:Medical physics. Medical radiology. Nuclear medicinePathologymedicine.medical_specialtymedicine.medical_treatmentlcsh:R895-920Neoplasm metastasisTentorium cerebelliPituitary neoplasmPituitary neoplasmsMalignancyArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePituitary adenomamedicineEndocrine systemRadiology Nuclear Medicine and imagingMEN1Ki-67 antigenNeoplasm metastasiPituitary carcinomabusiness.industryMagnetic resonance imaging MRISettore MED/37 - Neuroradiologiamedicine.diseasePituitary adenomaRadiation therapy030220 oncology & carcinogenesisPituitary neoplasms Pituitary carcinoma Pituitary adenoma Neoplasm metastasis Ki-67 antigen Magnetic resonance imaging MRIPituitary carcinomaSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessEuropean Journal of Radiology Open
researchProduct